{"id":"https://openalex.org/W4385738741","doi":"https://doi.org/10.1016/j.eclinm.2023.102131","title":"Parsaclisib, a PI3K\u03b4 inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study","display_name":"Parsaclisib, a PI3K\u03b4 inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study","publication_year":2023,"publication_date":"2023-08-01","ids":{"openalex":"https://openalex.org/W4385738741","doi":"https://doi.org/10.1016/j.eclinm.2023.102131","pmid":"https://pubmed.ncbi.nlm.nih.gov/37599908","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10433033"},"language":"en","primary_location":{"id":"doi:10.1016/j.eclinm.2023.102131","doi":"https://doi.org/10.1016/j.eclinm.2023.102131","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.eclinm.2023.102131","pdf_url":"http://www.thelancet.com/article/S2589537023003085/pdf","source":{"id":"https://openalex.org/S2898347799","display_name":"EClinicalMedicine","issn_l":"2589-5370","issn":["2589-5370"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"eClinicalMedicine","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://www.thelancet.com/article/S2589537023003085/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091882595","display_name":"Pier Luigi Zinzani","orcid":"https://orcid.org/0000-0002-2112-2651","observed_orcids":["https://orcid.org/0000-0002-2112-2651"]},"institutions":[{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":true,"raw_author_name":"Pier Luigi Zinzani","raw_affiliation_strings":["Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universit\u00e0 di Bologna, Bologna, Italy","IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \"Ser\u00e0gnoli\", Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universit\u00e0 di Bologna, Bologna, Italy","institution_ids":["https://openalex.org/I9360294"]},{"raw_affiliation_string":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \"Ser\u00e0gnoli\", Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088476247","display_name":"Marek Trn\u011bn\u00fd","orcid":"https://orcid.org/0000-0002-6952-6073","observed_orcids":["https://orcid.org/0000-0002-6952-6073"]},"institutions":[{"id":"https://openalex.org/I21250087","display_name":"Charles University","ror":"https://ror.org/024d6js02","country_code":"CZ","type":"education","lineage":["https://openalex.org/I21250087"]}],"countries":["CZ"],"is_corresponding":false,"raw_author_name":"Marek Trn\u011bn\u00fd","raw_affiliation_strings":["Charles University, General Hospital, Prague, Czech Republic"],"raw_orcid":"https://orcid.org/0000-0002-6952-6073","affiliations":[{"raw_affiliation_string":"Charles University, General Hospital, Prague, Czech Republic","institution_ids":["https://openalex.org/I21250087"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032462496","display_name":"Vincent Ribrag","orcid":"https://orcid.org/0000-0002-5221-353X","observed_orcids":["https://orcid.org/0000-0002-5221-353X"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Vincent Ribrag","raw_affiliation_strings":["Institut Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031900135","display_name":"Vittorio Ruggero Zilioli","orcid":"https://orcid.org/0000-0001-6915-2246","observed_orcids":["https://orcid.org/0000-0001-6915-2246"]},"institutions":[{"id":"https://openalex.org/I4210094195","display_name":"Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda","ror":"https://ror.org/00htrxv69","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210094195"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Vittorio Ruggero Zilioli","raw_affiliation_strings":["ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy","institution_ids":["https://openalex.org/I4210094195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056728544","display_name":"Jan Andrzej Walewski","orcid":"https://orcid.org/0000-0003-4247-2674","observed_orcids":["https://orcid.org/0000-0003-4247-2674"]},"institutions":[{"id":"https://openalex.org/I4210150880","display_name":"The Maria Sklodowska-Curie National Research Institute of Oncology","ror":"https://ror.org/04qcjsm24","country_code":"PL","type":"healthcare","lineage":["https://openalex.org/I4210150880"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Jan Walewski","raw_affiliation_strings":["Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland","institution_ids":["https://openalex.org/I4210150880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107297783","display_name":"Jacob Haaber Christensen","orcid":"https://orcid.org/0000-0003-1071-3218","observed_orcids":["https://orcid.org/0000-0003-1071-3218"]},"institutions":[{"id":"https://openalex.org/I2801498763","display_name":"Odense University Hospital","ror":"https://ror.org/00ey0ed83","country_code":"DK","type":"funder","lineage":["https://openalex.org/I2801498763"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Jacob Haaber Christensen","raw_affiliation_strings":["Department of Hematology, Odense University Hospital, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Odense University Hospital, Denmark","institution_ids":["https://openalex.org/I2801498763"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088580473","display_name":"Vincent Delwail","orcid":"https://orcid.org/0000-0003-0680-1418","observed_orcids":["https://orcid.org/0000-0003-0680-1418"]},"institutions":[{"id":"https://openalex.org/I4210111187","display_name":"Centre Hospitalier Universitaire de Poitiers","ror":"https://ror.org/029s6hd13","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210111187"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Vincent Delwail","raw_affiliation_strings":["CHU Poitiers, Poitiers, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHU Poitiers, Poitiers, France","institution_ids":["https://openalex.org/I4210111187"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Guillermo Rodriguez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210153139","display_name":"Hospital Universitario Virgen del Roc\u00edo","ror":"https://ror.org/04vfhnm78","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210153139"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Guillermo Rodriguez","raw_affiliation_strings":["Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario Virgen del Roc\u00edo, Seville, Spain","institution_ids":["https://openalex.org/I4210153139"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025499306","display_name":"Parameswaran Venugopal","orcid":"https://orcid.org/0000-0002-7518-9579","observed_orcids":["https://orcid.org/0000-0002-7518-9579"]},"institutions":[{"id":"https://openalex.org/I49886154","display_name":"Rush University","ror":"https://ror.org/01k9xac83","country_code":"US","type":"education","lineage":["https://openalex.org/I49886154"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Parameswaran Venugopal","raw_affiliation_strings":["Rush University, Chicago, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rush University, Chicago, IL, USA","institution_ids":["https://openalex.org/I49886154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082720713","display_name":"Morton Coleman","orcid":"https://orcid.org/0000-0002-8516-2513","observed_orcids":["https://orcid.org/0000-0002-8516-2513"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Morton Coleman","raw_affiliation_strings":["Clinical Research Alliance/Cornell Medicine, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Alliance/Cornell Medicine, New York, NY, USA","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113791155","display_name":"Caroline Dartigeas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095477","display_name":"Centre Hospitalier Universitaire de Tours","ror":"https://ror.org/00jpq0w62","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210095477"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Caroline Dartigeas","raw_affiliation_strings":["H\u00e9matologie et Th\u00e9rapie Cellulaire, CHRU de Tours, Tours, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H\u00e9matologie et Th\u00e9rapie Cellulaire, CHRU de Tours, Tours, France","institution_ids":["https://openalex.org/I4210095477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069410590","display_name":"Caterina Patti","orcid":"https://orcid.org/0009-0006-4316-9254","observed_orcids":["https://orcid.org/0009-0006-4316-9254"]},"institutions":[{"id":"https://openalex.org/I4210099059","display_name":"Ospedale Vincenzo Cervello","ror":"https://ror.org/00twmyj12","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210099059"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Caterina Patti","raw_affiliation_strings":["Department of Oncohematology Unit, Azienda Ospedali Riuniti Villa Sofia Cervello, Palmero, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncohematology Unit, Azienda Ospedali Riuniti Villa Sofia Cervello, Palmero, Italy","institution_ids":["https://openalex.org/I4210099059"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057084037","display_name":"Fabrizio Pane","orcid":"https://orcid.org/0000-0003-2563-4125","observed_orcids":["https://orcid.org/0000-0003-2563-4125"]},"institutions":[{"id":"https://openalex.org/I71267560","display_name":"University of Naples Federico II","ror":"https://ror.org/05290cv24","country_code":"IT","type":"education","lineage":["https://openalex.org/I71267560"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Fabrizio Pane","raw_affiliation_strings":["University of Naples Federico II, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Naples Federico II, Naples, Italy","institution_ids":["https://openalex.org/I71267560"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102788725","display_name":"Wojciech J. Jurczak","orcid":"https://orcid.org/0000-0003-1879-8084","observed_orcids":["https://orcid.org/0000-0003-1879-8084"]},"institutions":[{"id":"https://openalex.org/I4210150880","display_name":"The Maria Sklodowska-Curie National Research Institute of Oncology","ror":"https://ror.org/04qcjsm24","country_code":"PL","type":"healthcare","lineage":["https://openalex.org/I4210150880"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Wojciech Jurczak","raw_affiliation_strings":["Maria Sklodowska-Curie National Research Institute of Oncology, Krak\u00f3w, Poland"],"raw_orcid":"https://orcid.org/0000-0003-1879-8084","affiliations":[{"raw_affiliation_string":"Maria Sklodowska-Curie National Research Institute of Oncology, Krak\u00f3w, Poland","institution_ids":["https://openalex.org/I4210150880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033866359","display_name":"Micha\u0142 Taszner","orcid":"https://orcid.org/0000-0002-8437-2797","observed_orcids":["https://orcid.org/0000-0002-8437-2797"]},"institutions":[{"id":"https://openalex.org/I75124487","display_name":"Gda\u0144sk Medical University","ror":"https://ror.org/019sbgd69","country_code":"PL","type":"education","lineage":["https://openalex.org/I75124487"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Michal Taszner","raw_affiliation_strings":["Department of Haematology and Transplantology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Haematology and Transplantology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland","institution_ids":["https://openalex.org/I75124487"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066232993","display_name":"Shankara Paneesha","orcid":"https://orcid.org/0000-0002-7446-011X","observed_orcids":["https://orcid.org/0000-0002-7446-011X"]},"institutions":[{"id":"https://openalex.org/I4210104666","display_name":"Heartlands Hospital","ror":"https://ror.org/01bd5gh54","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210104666"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Shankara Paneesha","raw_affiliation_strings":["Birmingham Heartlands Hospital, Birmingham, UK"],"raw_orcid":"https://orcid.org/0000-0002-7446-011X","affiliations":[{"raw_affiliation_string":"Birmingham Heartlands Hospital, Birmingham, UK","institution_ids":["https://openalex.org/I4210104666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040883292","display_name":"Fred Zheng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fred Zheng","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE, USA","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071446481","display_name":"Douglas James DeMarini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas J. DeMarini","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE, USA","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056623428","display_name":"Wei Jiang","orcid":"https://orcid.org/0000-0002-9079-0792","observed_orcids":["https://orcid.org/0000-0002-9079-0792","https://orcid.org/0009-0005-9656-9262"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wei Jiang","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE, USA","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015821261","display_name":"Aidan G. Gilmartin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aidan Gilmartin","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE, USA","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030631799","display_name":"Amitkumar Mehta","orcid":"https://orcid.org/0000-0003-0537-4207","observed_orcids":["https://orcid.org/0000-0003-0537-4207"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amitkumar Mehta","raw_affiliation_strings":["UAB School of Medicine, Birmingham, AL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UAB School of Medicine, Birmingham, AL, USA","institution_ids":["https://openalex.org/I32389192","https://openalex.org/I4390039250"]}]}],"institutions":[],"countries_distinct_count":8,"institutions_distinct_count":18,"corresponding_author_ids":["https://openalex.org/A5091882595"],"corresponding_institution_ids":["https://openalex.org/I9360294"],"apc_list":{"value":5000,"currency":"USD","value_usd":5000},"apc_paid":{"value":5000,"currency":"USD","value_usd":5000},"fwci":2.268,"has_fulltext":true,"cited_by_count":12,"citation_normalized_percentile":{"value":0.8788227,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"62","issue":null,"first_page":"102131","last_page":"102131"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12212","display_name":"CNS Lymphoma Diagnosis and Treatment","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parsaclisib","display_name":"parsaclisib","score":0.9649999737739563},{"id":"https://openalex.org/keywords/pi3kdelta-inhibitor","display_name":"PI3K\u03b4 inhibitor","score":0.9890000224113464},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.9549999833106995},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.9350000023841858},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.5730000138282776},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8270000219345093},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.7829999923706055},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.8889999985694885},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.3779999911785126},{"id":"https://openalex.org/keywords/oral-kinase-inhibitor","display_name":"oral kinase inhibitor","score":0.3400000035762787},{"id":"https://openalex.org/keywords/b-cell-malignancies","display_name":"B-cell malignancies","score":0.6100000143051147}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7981752157211304},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6911798715591431},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6757974028587341},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.5807486772537231},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5432648658752441},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5399702787399292},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4957674443721771},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4849091172218323},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.45907801389694214},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.4555649757385254},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4138241112232208},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.35624170303344727},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.28458261489868164},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.16257363557815552},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":6,"locations":[{"id":"doi:10.1016/j.eclinm.2023.102131","doi":"https://doi.org/10.1016/j.eclinm.2023.102131","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.eclinm.2023.102131","pdf_url":"http://www.thelancet.com/article/S2589537023003085/pdf","source":{"id":"https://openalex.org/S2898347799","display_name":"EClinicalMedicine","issn_l":"2589-5370","issn":["2589-5370"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"eClinicalMedicine","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10433033","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10433033","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10433033/pdf/main.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"eClinicalMedicine","raw_type":"Text"},{"id":"pmid:37599908","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37599908","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"EClinicalMedicine","raw_type":"Journal Article"},{"id":"pmh:oai:sdu.dk:openaire/984d5d11-a7c0-4915-a519-fe8e7d375d21","doi":null,"is_oa":true,"landing_page_url":"https://portal.findresearcher.sdu.dk/da/publications/984d5d11-a7c0-4915-a519-fe8e7d375d21","pdf_url":null,"source":{"id":"https://openalex.org/S4306400423","display_name":"University of Southern Denmark Research Portal (University of Southern Denmark)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I177969490","host_organization_name":"University of Southern Denmark","host_organization_lineage":["https://openalex.org/I177969490"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Zinzani, P L, Trn\u011bn\u00fd, M, Ribrag, V, Zilioli, V R, Walewski, J, Christensen, J H, Delwail, V, Rodriguez, G, Venugopal, P, Coleman, M, Dartigeas, C, Patti, C, Pane, F, Jurczak, W, Taszner, M, Paneesha, S, Zheng, F, DeMarini, D J, Jiang, W, Gilmartin, A & Mehta, A 2023, 'Parsaclisib, a PI3K\u03b4 inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205) : a phase 2 study', eClinicalMedicine, vol. 62, 102131. https://doi.org/10.1016/j.eclinm.2023.102131","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:cris.unibo.it:11585/960110","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/11585/960110","pdf_url":null,"source":{"id":"https://openalex.org/S4306402579","display_name":"Archivio istituzionale della ricerca (Alma Mater Studiorum Universit\u00e0 di Bologna)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210117483","host_organization_name":"Istituto di Ematologia di Bologna","host_organization_lineage":["https://openalex.org/I4210117483"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:doaj.org/article:2eed59c08fdd45b896bddf048a659297","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/2eed59c08fdd45b896bddf048a659297","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"EClinicalMedicine, Vol 62, Iss , Pp 102131- (2023)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1016/j.eclinm.2023.102131","doi":"https://doi.org/10.1016/j.eclinm.2023.102131","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.eclinm.2023.102131","pdf_url":"http://www.thelancet.com/article/S2589537023003085/pdf","source":{"id":"https://openalex.org/S2898347799","display_name":"EClinicalMedicine","issn_l":"2589-5370","issn":["2589-5370"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"eClinicalMedicine","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320312570","display_name":"Jazz Pharmaceuticals","ror":"https://ror.org/055mhsv54"},{"id":"https://openalex.org/F4320313971","display_name":"TG Therapeutics","ror":"https://ror.org/00pwykz63"},{"id":"https://openalex.org/F4320316491","display_name":"MEI Pharma","ror":"https://ror.org/02bgfrc80"},{"id":"https://openalex.org/F4320317235","display_name":"BeiGene","ror":"https://ror.org/012v2c923"},{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"},{"id":"https://openalex.org/F4320327235","display_name":"Servier","ror":"https://ror.org/034e7c066"},{"id":"https://openalex.org/F4320328456","display_name":"Italfarmaco","ror":"https://ror.org/05xsppr58"},{"id":"https://openalex.org/F4320330792","display_name":"EUSA Pharma","ror":"https://ror.org/01p7jrr32"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320332736","display_name":"Novartis Pharma","ror":"https://ror.org/0013shd50"},{"id":"https://openalex.org/F4320333648","display_name":"Pharmacyclics","ror":"https://ror.org/03hm8w204"},{"id":"https://openalex.org/F4320338262","display_name":"Daiichi Sankyo Europe","ror":"https://ror.org/01qhj1g70"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4385738741.pdf","grobid_xml":"https://content.openalex.org/works/W4385738741.grobid-xml"},"referenced_works_count":29,"referenced_works":["https://openalex.org/W1829587101","https://openalex.org/W1992477322","https://openalex.org/W2036266060","https://openalex.org/W2070073293","https://openalex.org/W2112134595","https://openalex.org/W2119147717","https://openalex.org/W2124432094","https://openalex.org/W2134861285","https://openalex.org/W2598700764","https://openalex.org/W2762226752","https://openalex.org/W2774522106","https://openalex.org/W2801598494","https://openalex.org/W2907337505","https://openalex.org/W2913987637","https://openalex.org/W2917721259","https://openalex.org/W2945874655","https://openalex.org/W2980771844","https://openalex.org/W3018806545","https://openalex.org/W3046825703","https://openalex.org/W3087469327","https://openalex.org/W3134524629","https://openalex.org/W3185756680","https://openalex.org/W3212937025","https://openalex.org/W4200583252","https://openalex.org/W4220666128","https://openalex.org/W4246245428","https://openalex.org/W4296468337","https://openalex.org/W4296789278","https://openalex.org/W6757607642"],"related_works":["https://openalex.org/W3096345204","https://openalex.org/W3217796278","https://openalex.org/W4231622124","https://openalex.org/W4389979814","https://openalex.org/W3097629244","https://openalex.org/W2959327776","https://openalex.org/W4385975290","https://openalex.org/W2917721259","https://openalex.org/W4213422983","https://openalex.org/W3097179004"],"abstract_inverted_index":{"Background:":[0],"Parsaclisib":[1,245],"is":[2],"a":[3,190,200,282,293],"potent":[4],"and":[5,33,57,139,199,241,259,272,292,353],"highly":[6,284],"selective":[7],"PI3K\u03b4":[8,286],"inhibitor":[9,74,287],"that":[10],"has":[11],"shown":[12],"clinical":[13,169,290,321],"benefit":[14,322],"in":[15,39,127,142,224,277,311,328],"patients":[16,40,126,141,223,271,314,329],"with":[17,41,52,60,64,189,315,325],"relapsed/refractory":[18],"(R/R)":[19],"B-cell":[20],"malignancies.":[21],"In":[22,171],"this":[23],"phase":[24],"2":[25,144],"study":[26],"(CITADEL-205;":[27],"NCT03235544,":[28],"EudraCT":[29],"2017-003148-19),":[30],"the":[31,116,172,175,225],"efficacy":[32],"safety":[34,295,352],"of":[35,196,203,207,220,235,262,302,338,347],"parsaclisib":[36,79,89,98,156,326],"was":[37,109,161,186,323],"evaluated":[38],"R/R":[42,55,312],"mantle":[43],"cell":[44],"lymphoma":[45],"(MCL).":[46],"Methods:":[47],"Patients":[48],"\u226518":[49],"years":[50],"old":[51],"pathologically":[53],"confirmed":[54],"MCL":[56,313],"prior":[58,317],"treatment":[59],"1-3":[61],"systemic":[62],"therapies,":[63],"(cohort":[65,69],"1)":[66],"or":[67,97,248,307],"without":[68],"2)":[70],"previous":[71],"Bruton":[72],"kinase":[73],"(BTKi)":[75],"treatment,":[76],"received":[77,155,333],"oral":[78],"20":[80,90],"mg":[81,91,100],"once-daily":[82],"(QD)":[83],"for":[84,179,183,341],"8":[85],"weeks,":[86],"then":[87],"either":[88],"once-weekly":[92],"(weekly":[93],"dosing":[94,103],"group":[95,104],"[WG])":[96],"2.5":[99],"QD":[101],"(daily":[102],"[DG]).":[105],"The":[106,158],"primary":[107,117],"endpoint":[108],"objective":[110],"response":[111,192,204],"rate":[112,193],"(ORR).":[113],"Findings:":[114],"At":[115],"analysis":[118,166],"data":[119],"cutoff":[120],"on":[121],"January":[122],"15,":[123],"2021,":[124],"53":[125],"cohort":[128,143,160],"1":[129],"(BTKi-experienced)":[130],"(WG,":[131,146],"n":[132,136,147,151],"=":[133,137,148,152],"12;":[134],"DG:":[135,150],"41)":[138],"108":[140],"(BTKi-naive)":[145],"31;":[149],"77)":[153],"had":[154,331],"monotherapy.":[157],"BTKi-experienced":[159],"closed":[162],"after":[163],"an":[164],"interim":[165],"demonstrated":[167,288],"limited":[168],"benefit.":[170],"BTKi-naive":[173,226],"cohort,":[174],"ORR":[176],"(95%":[177,194,205],"CI)":[178,195,206],"DG":[180],"(dosing":[181],"selected":[182],"further":[184,345],"study)":[185],"70.1%":[187],"(58.6%-80.0%),":[188],"complete":[191],"15.6%":[197],"(8.3%-25.6%)":[198],"median":[201],"duration":[202],"12.1":[208],"(9.0-not":[209],"evaluable)":[210],"months.":[211],"Treatment-emergent":[212],"adverse":[213,309],"events":[214],"(TEAEs)":[215],"occurred":[216,231,253],"among":[217,232,254],"90.7%":[218],"(98/108)":[219],"all":[221],"treated":[222],"cohort.":[227],"Grade":[228],"\u22653":[229,306],"TEAEs":[230,252,266],"62.0%":[233],"(67/108)":[234],"patients,":[236,263],"including":[237],"diarrhoea":[238],"(13.9%,":[239],"15/108)":[240],"neutropenia":[242],"(8.3%,":[243],"9/108).":[244],"interruption,":[246],"reduction,":[247],"discontinuation":[249,298],"due":[250],"to":[251,274,350],"47.2%":[255],"(51/108),":[256],"8.3%":[257],"(9/108),":[258],"25.0%":[260],"(27/108)":[261],"respectively.":[264],"Fatal":[265],"were":[267],"experienced":[268],"by":[269],"six":[270],"determined":[273],"be":[275],"treatment-related":[276],"one":[278],"patient.":[279],"Interpretation:":[280],"Parsaclisib,":[281],"potent,":[283],"selective,":[285],"meaningful":[289],"benefits":[291],"manageable":[294],"profile":[296],"(25.0%":[297],"rate,":[299],"low":[300],"incidences":[301],"individually":[303],"reported":[304],"grade":[305],"serious":[308],"events)":[310],"no":[316],"BTKi":[318,334],"therapy.":[319],"Limited":[320],"observed":[324],"monotherapy":[327],"who":[330],"previously":[332],"treatment.":[335],"Future":[336],"development":[337],"PI3K":[339],"inhibitors":[340],"NHL":[342],"will":[343],"require":[344],"investigation":[346],"dose":[348],"optimisation":[349],"improve":[351],"long-term":[354],"survival.":[355],"Funding:":[356],"Incyte":[357],"Corporation.":[358]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-08-11T00:00:00"}